Literature DB >> 21406269

Myeloid cell population dynamics in healthy and tumor-bearing mice.

Satoshi Ueha1, Francis H W Shand, Kouji Matsushima.   

Abstract

Tumor growth is often associated with the aberrant systemic accumulation of myeloid-derived suppressor cells (MDSCs), which are a heterogenous population of cells composed of polymorphonuclear neutrophils, monocytes, macrophages, dendritic cells and early myeloid precursors. These MDSCs are thought to suppress anti-tumor T cell responses in both tumor tissues and secondary lymphoid tissues. Accumulation of MDSCs in these target tissues is a dynamic process associated with medullary and extramedullary myelopoiesis and subsequent cellular migration. Here, we review the current understanding of the cellular, molecular, hematological and anatomical principles of MDSC development and migration in tumor-bearing mice. We also discuss the therapeutic potential of chemokines that influence the balance between MDSC subpopulations.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21406269     DOI: 10.1016/j.intimp.2011.03.003

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  41 in total

Review 1.  The multifaceted functions of neutrophils.

Authors:  Tanya N Mayadas; Xavier Cullere; Clifford A Lowell
Journal:  Annu Rev Pathol       Date:  2013-09-16       Impact factor: 23.472

2.  Role of CD11b+Gr-1+ myeloid cells in AGEs-induced myocardial injury in a mice model of acute myocardial infarction.

Authors:  Tongqing Yao; Wenbin Lu; Jian Zhu; Xian Jin; Genshan Ma; Yuepeng Wang; Shu Meng; Yachen Zhang; Yigang Li; Chengxing Shen
Journal:  Int J Clin Exp Pathol       Date:  2015-03-01

Review 3.  Complex interplay between tumor microenvironment and cancer therapy.

Authors:  Minhong Shen; Yibin Kang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

4.  CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma.

Authors:  Britnie R James; Kristin G Anderson; Erik L Brincks; Tamara A Kucaba; Lyse A Norian; David Masopust; Thomas S Griffith
Journal:  Cancer Immunol Immunother       Date:  2014-08-21       Impact factor: 6.968

Review 5.  Integrating new discoveries into the "vicious cycle" paradigm of prostate to bone metastases.

Authors:  Leah M Cook; Gemma Shay; Arturo Araujo; Arturo Aruajo; Conor C Lynch
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

6.  The protumorigenic potential of FTY720 by promoting extramedullary hematopoiesis and MDSC accumulation.

Authors:  Y Li; T Zhou; Y Wang; C Ning; Z Lv; G Han; J C Morris; E N Taylor; R Wang; H Xiao; C Hou; Y Ma; B Shen; J Feng; R Guo; Y Li; G Chen
Journal:  Oncogene       Date:  2017-02-20       Impact factor: 9.867

7.  Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis.

Authors:  Mélanie Demers; Daniela S Krause; Daphne Schatzberg; Kimberly Martinod; Jaymie R Voorhees; Tobias A Fuchs; David T Scadden; Denisa D Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-23       Impact factor: 11.205

Review 8.  The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

Authors:  Vinit Kumar; Sima Patel; Evgenii Tcyganov; Dmitry I Gabrilovich
Journal:  Trends Immunol       Date:  2016-02-06       Impact factor: 16.687

9.  Heme catabolism by tumor-associated macrophages controls metastasis formation.

Authors:  Francesca Maria Consonni; Augusto Bleve; Maria Grazia Totaro; Mariangela Storto; Paolo Kunderfranco; Alberto Termanini; Fabio Pasqualini; Chiara Alì; Chiara Pandolfo; Francesco Sgambelluri; Giulia Grazia; Mario Santinami; Andrea Maurichi; Massimo Milione; Marco Erreni; Andrea Doni; Marco Fabbri; Laura Gribaldo; Eliana Rulli; Miguel Parreira Soares; Valter Torri; Roberta Mortarini; Andrea Anichini; Antonio Sica
Journal:  Nat Immunol       Date:  2021-04-26       Impact factor: 25.606

10.  Notch signaling defects in NK cells in patients with cancer.

Authors:  Gulnur K Zakiryanova; Elena Kustova; Nataliya T Urazalieva; Emile T Baimukhametov; Valeriy A Makarov; Gulmariya M Turaly; Galina V Shurin; Zarema M Biyasheva; Narymzhan N Nakisbekov; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2020-10-21       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.